2024-03-28T10:00:55Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/537452022-11-17T02:08:08Zhdl_2115_20044hdl_2115_124Effect of tenascin-X together with vascular endothelial growth factor A on cell proliferation in cultured embryonic hearts.Ikuta, TomokiAriga, HiroyoshiMatsumoto, Ken-ichitenascin-Xvascular endothelial growth factor Aextracellular matrix499AnimalsCell Division/drug effectsCell Division/physiologyCulture TechniquesEmbryo, MammalianEndocardium/cytologyEndocardium/drug effectsEndocardium/physiologyEndothelial Growth Factors/pharmacologyEndothelial Growth Factors/physiologyFemaleHumansMiceMice, Inbred C57BLMice, Inbred CBAMice, Inbred ICRMice, KnockoutPregnancyTenascin/deficiencyTenascin/geneticsTenascin/pharmacologyVascular Endothelial Growth Factor AVascular Endothelial Growth Factor BTenascin-X (TNX) is a large glycoprotein that appears in extracellular matrices. Previously, we demonstrated that TNX binds to vascular endothelial growth factors A and B (VEGF-A and -B) and that VEGF-B in combination with TNX induces DNA synthesis in endothelial cells via increased signals mediated by the VEGFR-1 receptor. In this study, we investigated the effect of TNX with VEGF-A on the cell proliferation in embryonic mouse heart explants from either wild-type (TNX+/+) or TNX-deficient (TNX-/-) mice. The addition of VEGF-A to the explants from TNX+/+ mice increased cell proliferation by 1.5 fold compared with that in TNX-/- mice, indicating that TNX with VEGF family member plays an important role in the control of endothelial cell proliferation in vivo.The Pharmaceutical Society of JapanJournal Articleapplication/pdfhttp://hdl.handle.net/2115/53745https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/53745/1/115_Ariga_2001_Biol_Pharm_Bull.pdf0918-6158Biological & pharmaceutical bulletin2411132013232001-11enginfo:pmid/11725972info:doi/10.1248/bpb.24.1320publisher